| 1 |
27329169 | Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer. | 2016 Jul |
5 |
| 2 |
25425972 | Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. | 2014 Nov |
1 |
| 3 |
22414726 | Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. | 2012 Jun 15 |
1 |
| 4 |
22420423 | Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. | 2012 Mar 15 |
5 |
| 5 |
20662736 | Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. | 2010 Aug |
1 |
| 6 |
14966265 | ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage. | 2004 Mar |
1 |